Abstract
IntroductionMepolizumab was the first anti-IL5 monoclonal antibody (mAb) to be licensed for severe eosinophilic asthma (SEA), and its use reduces exacerbation rate and maintenance oral corticosteroid (mOCS) requirement. A significant...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
